Ten years of anti-vascular endothelial growth factor therapy

Nature Reviews. Drug Discovery
Napoleone Ferrara, Anthony P Adamis

Abstract

The targeting of vascular endothelial growth factor A (VEGFA), a crucial regulator of both normal and pathological angiogenesis, has revealed innovative therapeutic approaches in oncology and ophthalmology. The first VEGFA inhibitor, bevacizumab, was approved by the US Food and Drug Administration in 2004 for the first-line treatment of metastatic colorectal cancer, and the first VEGFA inhibitors in ophthalmology, pegaptanib and ranibizumab, were approved in 2004 and 2006, respectively. To mark this tenth anniversary of anti-VEGFA therapy, we discuss the discovery of VEGFA, the successes and challenges in the development of VEGFA inhibitors and the impact of these agents on the treatment of cancers and ophthalmic diseases.

References

Sep 30, 1992·Biochemical and Biophysical Research Communications·B I TermanP Böhlen
Jan 1, 1991·Annual Review of Physiology·M Klagsbrun, P A D'Amore
Jan 1, 1992·The Journal of Clinical Investigation·L B JakemanN Ferrara
Oct 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·D MaglioneM G Persico
Jan 23, 1987·Science·J Folkman, M Klagsbrun
Jan 1, 1987·Nouvelle Revue Française D'hématologie·A Camez, G Tobelem
Jun 15, 1989·Biochemical and Biophysical Research Communications·N Ferrara, W J Henzel
Aug 12, 1971·The New England Journal of Medicine·J Folkman
Nov 1, 1984·Archives of Ophthalmology·F L FerrisL Hyman
Nov 7, 1995·Proceedings of the National Academy of Sciences of the United States of America·L P AielloL E Smith
Mar 19, 1996·Proceedings of the National Academy of Sciences of the United States of America·B OlofssonU Eriksson
Oct 15, 1996·Proceedings of the National Academy of Sciences of the United States of America·M OrlandiniS Oliviero
Jan 1, 1996·Annual Review of Cell and Developmental Biology·M Raghavan, P J Bjorkman
Apr 18, 1997·The Journal of Biological Chemistry·M BacaJ A Wells
Feb 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M S GordonD Adelman
Feb 28, 2001·Proceedings of the National Academy of Sciences of the United States of America·D FukumuraR K Jain

❮ Previous
Next ❯

Citations

May 11, 2016·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·John L HamiltonHee-Jeong Im
Jul 2, 2016·Nature Reviews. Neurology·Christian LangePeter Carmeliet
Aug 31, 2016·British Journal of Cancer·Madelon Q WentinkHenk M W Verheul
Oct 13, 2016·The New England Journal of Medicine·Javid J Moslehi
Feb 14, 2017·Bioorganic & Medicinal Chemistry·Mingze QinPing Gong
Apr 4, 2017·Current Opinion in Chemical Biology·Jun Woo Kim, Jennifer R Cochran
Mar 24, 2017·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Robert Roskoski
Mar 6, 2017·Cancer Letters·Maria Riesco-MartinezUrban Emmenegger
May 23, 2017·Nature Reviews. Drug Discovery·Pipsa SaharinenKari Alitalo
Apr 7, 2017·Macromolecular Bioscience·Matthias Bartneck
Jan 14, 2017·Molecular Oncology·Daniele V F TaurielloEduard Batlle
Jul 15, 2017·Nature Reviews. Cancer·Michele De PalmaTatiana V Petrova
May 10, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A BamiasE Pujade-Lauraine
Mar 13, 2018·Nanoscale·Pravin BhattaraiZhifei Dai
Oct 12, 2017·European Journal of Drug Metabolism and Pharmacokinetics·Matteo MorottiSimon Lord
Oct 19, 2017·International Journal of Molecular Sciences·Zhenjian ZhuoBaoting Zhang
Apr 5, 2018·Journal of Experimental & Clinical Cancer Research : CR·Anastasia ChillàAnna Laurenzana
Apr 25, 2018·International Journal of Molecular Sciences·Chloe J PeachJeanette Woolard
Jan 24, 2018·Biomedical Materials·Agnes E HaggertyMartin Oudega
Nov 1, 2017·European Journal of Nuclear Medicine and Molecular Imaging·Weijun WeiWeibo Cai
Nov 18, 2017·Oncoimmunology·Claire Vanpouille-BoxLorenzo Galluzzi
Jun 14, 2017·Proceedings of the National Academy of Sciences of the United States of America·Yin ZhangYihai Cao
Dec 22, 2017·JCI Insight·Gabriel VelezVinit B Mahajan
Feb 15, 2018·Platelets·Julia Etulain
Dec 7, 2017·Oncoimmunology·Mariona CaboLorenzo Galluzzi
Aug 12, 2016·Journal of the European Academy of Dermatology and Venereology : JEADV·D MiyamotoV Aoki
Aug 10, 2018·Future Medicinal Chemistry·Jaclyn J RenfrowRoy E Strowd
Aug 18, 2018·The Cancer Journal·Napoleone Ferrara, Daniel S Chen
Oct 31, 2018·International Journal of Cancer. Journal International Du Cancer·Yun XiaGang Wu
Dec 18, 2018·Expert Opinion on Therapeutic Patents·Giuseppina De Simone
Aug 8, 2018·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Ruslan RustMartin E Schwab

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

© 2022 Meta ULC. All rights reserved